For laboratory research use only.
Hexarelin (examorelin) is a synthetic hexapeptide growth hormone–releasing peptide and GHS-R1a agonist. Its sequence is commonly given as His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2—a GHRP-6 analog with a methylated D-tryptophan substitution.
Classic secretagogue identity
Hexarelin entered the literature as a potent GH-releasing hexapeptide related to GHRP-6. It belongs with ghrelin-receptor tools, not with GHRH analogs. Comparative secretagogue panels often include hexarelin when investigators want another GHS-R1a chemotype beside GHRP-2, GHRP-6, or ipamorelin.
Beyond routine GH-axis endpoints
Some hexarelin papers explore specialized models outside simple pituitary GH release. Examples include attenuation of abdominal aortic aneurysm formation with effects on smooth-muscle phenotype switching in a reported animal study (hexarelin AAA model), modulation of inflammation and fibrosis in acute lung injury models (hexarelin lung injury), and cardiac-focused imaging/pharmacology work (hexarelin cardiac study). Those branches can be legitimate research lines and still be irrelevant to a pituitary-only assay—cite what you use.
Class boundaries
Hexarelin ≠ GHRP-2 ≠ GHRP-6 ≠ ipamorelin. Shared receptor family membership is not identity. GHRPs remain distinct from GHRH analogs such as sermorelin, tesamorelin, or CJC-1295.
Sources
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. (Microvasc Res, 2022, PMID 34856183)
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. (Drug Target Insights, 2021, PMID 34871336)
- Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. (Front Physiol, 2021, PMID 35126171)